comparemela.com

Latest Breaking News On - Central licensing authority on - Page 1 : comparemela.com

Welcome To IANS Live - NATION - Bharat Biotech gets permission to manufacture Covaxin for sale (Lead, correcting para 1)

Photo Credit: IANS IANSLive New Delhi, Jan 3 (IANS) The Central Licensing Authority on Sunday granted permission to Hyderabad-based Bharat Biotech to manufacture Covaxin for sale and distribution, after the indigenous coronavirus vaccine received regulatory approval for emergency use. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 03-January-2021

Bharat Biotech gets permission to manufacture Covaxin for sale

Welcome To IANS Live - NATION - Bharat Biotech gets permission to manufacture Covaxin for sale

Photo Credit: IANS IANSLive New Delhi, Jan 3 (IANS) The Central Licensing Authority on Saturday granted permission to Hyderabad-based Bharat Biotech to manufacture Covaxin for sale and distribution, after the indigenous coronavirus vaccine received regulatory approval for emergency use. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 03-January-2021

Bharat Biotech Covaxin licensing permission DCGI coronavirus vaccine

URL copied Bharat Biotech gets licensing permission to manufacture Covaxin The Central Licensing Authority on Sunday granted permission to Bharat Biotech to manufacture Covaxin for sale and distribution, hours after the Drug Controller General of India (DCGI) approved the coronavirus vaccine for restricted emergency use.  The Hyderabad-based company has been asked to submit safety, efficacy and immunogenicity data from the ongoing phase I, II and III clinical trials till the completion.  The firm should provide the protocol for rolling out for the restricted use of the vaccine in emergency situation. The firm should provide the updates prescribing information/package insert and summary of product characteristics for whole virion inactivated coronavirus vaccine (BBV152b) and also disseminate the necessary information, instructions and educational materials through their website, the DCGI said today. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.